FDA approves Gilead’s daily HIV pill to simplify treatment

• Bixlenvo is priced at $4,595 for a 30-day supply, in line with other daily single-tablet HIV treatments, with patient assistance programs available for uninsured and insured patients
• The drug combines bictegravir (from blockbuster Biktarvy) with lenacapavir, a first-in-class capsid inhibitor central to Gilead's long-term HIV strategy including daily pills and six-month injectables
• Phase 3 trials included patients with median age 60 taking 2-11 pills daily before switching, with most common side effects being headache, nausea and diarrhea in at least 2% of participants

FDA Approves Gilead's Bixlenvo: New Daily HIV Treatment Option

The FDA has approved Gilead's Bixlenvo, a once-daily HIV pill designed to simplify treatment for patients whose virus is suppressed but who face challenges with existing therapies. The drug combines bictegravir (the backbone of Gilead's blockbuster Biktarvy) with lenacapavir, a first-in-class capsid inhibitor central to the company's HIV strategy.

Target Market and Pricing:

Bixlenvo targets an estimated 5% or more of U.S. HIV patients—those unable to use current single-tablet options due to drug resistance, side effects, or medication interactions. The list price is $4,595 for a 30-day supply, matching other daily HIV treatments. Gilead offers patient assistance programs for uninsured patients and co-pay support for those with commercial insurance.

Clinical Evidence:

Approval was based on two Phase 3 trials (ARTISTRY-1 and another study) involving adults with suppressed HIV. Participants, many with median age 60 and taking 2-11 pills daily, maintained viral suppression at 48 weeks with minimal side effects. Common adverse events included headache, nausea, and diarrhea (≥2% of participants).

Strategic Implications:

Dr. Jared Baeten, Gilead's clinical development head, emphasized the drug addresses an unmet need for patients with complex regimens while expanding options for those on simpler treatments like Biktarvy. Bixlenvo is part of Gilead's broader strategy to build diverse HIV treatment options around lenacapavir, including daily pills, weekly oral regimens, and long-acting injectables.

The two-drug combination attacks HIV through different mechanisms, providing high efficacy and resistance protection—critical for patients with limited remaining treatment options due to decades of virus evolution.